

Vincenzo Castiglione

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6838386/vincenzo-castiglione-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33 papers	469 citations	10 h-index	21 g-index
48 ext. papers	842 ext. citations	5.7 avg, IF	4.31 L-index

#	Paper	IF	Citations
33	Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.. <i>European Heart Journal Cardiovascular Imaging</i> , 2022 ,	4.1	1
32	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. <i>Heart Failure Reviews</i> , 2021 , 26, 881-890	5	10
31	Biomarkers for the diagnosis and management of heart failure. <i>Heart Failure Reviews</i> , 2021 , 1	5	11
30	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13598	4.6	3
29	Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction. <i>Clinical Research in Cardiology</i> , 2021 , 110, 711-724	6.1	1
28	A simple echocardiographic score to rule out cardiac amyloidosis. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13449	4.6	6
27	Use of biomarkers to diagnose and manage cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2021 , 23, 217-230	12.3	12
26	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. <i>JACC: Case Reports</i> , 2021 , 3, 450-454	1.2	0
25	Current and emerging drug targets in heart failure treatment. <i>Heart Failure Reviews</i> , 2021 , 1	5	4
24	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2021 , 1	5	3
23	Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021 , 1-7	2.7	1
22	Coronary Artery Anomalies. <i>Circulation</i> , 2021 , 144, 983-996	16.7	7
21	The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis?. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 1877-1878	8.4	
20	Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women. <i>JACC: Case Reports</i> , 2020 , 2, 2400-2403	1.2	1
19	Cardiac magnetic resonance in patients with muscular dystrophies. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320923052	3.9	4
18	Cardiovascular disease and COVID-19: les liaisons dangereuses. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1017-1025	3.9	14
17	Safety and Efficacy of Amiodarone in a Patient With COVID-19. <i>JACC: Case Reports</i> , 2020 , 2, 1307-1310	1.2	10

16	Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. <i>European Journal of Internal Medicine</i> , 2020 , 80, 66-72	3.9	16
15	Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis. <i>Molecular Genetics & Genomic Medicine</i> , 2020 , 8, e1182	2.3	1
14	The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2020 , 307, 180-186	3.2	4
13	Statin therapy in COVID-19 infection. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 258-259	6.4	116
12	Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Letter regarding the article Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial <i>European Journal of Heart Failure</i> , 2020 , 22, 1934-1935	12.3	
11	High-sensitivity cardiac troponin T and NT-proBNP for ruling-in and ruling-out of cardiac amyloidosis. <i>European Heart Journal</i> , 2020 , 41,	9.5	1
10	Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 909-920	8.4	47
9	Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1795-1807	15.1	26
8	Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 494-510	3.9	56
7	Treatment of cardiac transthyretin amyloidosis: an update. <i>European Heart Journal</i> , 2019 , 40, 3699-3706	9.5	75
6	sST2 for Outcome Prediction in Acute Heart Failure: Which Is the Best Cutoff?. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 478-479	15.1	3
5	What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas. <i>JACC: Case Reports</i> , 2019 , 1, 657-662	1.2	1
4	Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 1419-1430	3.9	7
3	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2017 , 5, 735-743	7.4	17
2	Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1718-1724	3.9	1
1	Diagnostic Tools: The Easier, the Better 2017 , 219-234		